Here we describe how to isolate carbohydrate-specific t cell clones (for which we propose the designation 'tcarbs') after stimulation by two glycoconjugate vaccines. We describe how to prepare, purify and characterize two model glycoconjugate vaccines that can be used to generate tcarbs. these glycoconjugate vaccines (GBsIII-oVa and GBsIII-tt) are synthesized by conjugation of type III group B streptococcal polysaccharide (GBsIII) to ovalbumin (oVa) or tetanus toxoid (tt). upon immunization of mice with GBsIII-oVa, carbohydrate epitopes are presented to and recognized by cD4 + t cells. subsequently, polysaccharide-recognizing cD4 + t cells are expanded in vitro by stimulating splenic cD4 + t cells with GBsIII-tt. the sequential use of two distinct glycoconjugate vaccines containing the same polysaccharide conjugated to heterologous carrier proteins selects for and expands carbohydratespecific t cells. this protocol can readily be adapted to study the stimulation of the immune system by alternative glycoconjugate vaccines. this protocol takes 1-2 years to complete.
IntroDuctIon
Here we describe detailed protocols for the isolation of carbohydrate-specific CD4 + T cell clones (Tcarbs) derived from stimulation by two model glycoconjugate vaccines, whose generation was first described in ref. 1 . Isolation of Tcarbs is essential to more fully understand the immune interactions between glycoconjugate vaccines and the immune system. Elucidation of the structural requirements for T cell stimulation will enable design and synthesis of knowledge-based vaccines that are highly protective against many different bacterial pathogens. This protocol can be adapted to study the presence and isolation of Tcarbs stimulated by epitopes generated from capsular polysaccharides (CPSs) of other pathogens such as Haemophilus influenzae, Streptococcus pneumonia and Neisseria meningitidis.
Most CPSs expressed by pathogenic bacteria have been considered T cell-independent antigens 2-6 because they fail to induce T cell-mediated immune responses such as IgM-to-IgG class switching 4 , a booster antibody response (i.e., a secondary antibody response after recall immunization) and T cell memory 5 . T cell help for B cells that produce IgG antibodies to the polysaccharide component [6] [7] [8] [9] [10] [11] [12] can be recruited by immunization with a glycoconjugate vaccine prepared by covalent coupling of a CPS to a carrier protein. CD4 + T cells recognize peptides in the context of major histocompatibility class II (MHCII) molecules through their variant T cell receptor (TCR). Therefore, the traditional view of the mechanism for induction of an IgG memory-type immune response by glycoconjugate vaccines has been that the peptides generated from the carrier-protein portion of the conjugate vaccine are presented to CD4 + T cells, with consequent induction of B cell secretion of IgG antibodies to the carbohydrate portion.
We recently showed that, upon uptake into the endolysosomes of antigen-presenting cells (APCs), the carbohydrate portion of a model glycoconjugate vaccine undergoes depolymerization along with digestion of the carrier protein to create carbohydrate T cell epitopes in the form of peptide-carbohydrate conjugates, which we have termed glycan p peptides 1 . These epitopes formed in the endolysosome bind to MHCII through the peptide portion and are subsequently presented on the APC surface with the carbohydrate epitope positioned for recognition by the TCR. Recognition of the carbohydrate in the presence of MHCII drives CD4 + T cell help for antibody-producing B cells. On the basis of these results, we have formulated a mechanism that revises classical teaching about antigen presentation of glycoconjugates and in which T cell recognition of carbohydrates is central.
Comparison with other methods
Several glycopeptide-specific T-hybridoma cell lines and T cell clones have been established by other investigators using an immunization regimen distinctly different from ours [13] [14] [15] . In these studies, mice were immunized with either a natural glycopeptide/glycoprotein or a glycopeptide consisting of a monosaccharide or an oligosaccharide conjugated to a synthetic peptide that corresponded to a CD4 + T cell epitope of a model antigen. The same glycopeptide was used to stimulate T cells in vitro. CD4 + T cell recognition of glycopeptides containing a small number of sugars generated by the processing of natural glycoproteins (e.g., type II collagen or hen egg lysozyme glycopeptides) 13, 15 is dependent upon the presentation of a few glycosylated residues on a peptide. In these protocols, the majority of immune lymphocytes obtained might have been CD4 + T cells specific for the peptide portion of the glycopeptide used for both in vivo priming/boosting and in vitro re-stimulation, and the frequency of carbohydrate-specific T cells might have been diminished. In contrast, we opted to immunize mice and re-stimulate Isolation of carbohydrate-specific CD4 + T cell clones from mice after stimulation by two model glycoconjugate vaccines immune cells in culture with glycoconjugates containing the same polysaccharide but different carrier proteins-i.e., GBSIII-OVA and GBSIII-TT. Because immunization of mice with GBSIII-OVA enriches for both Tcarbs and OVA-specific T cells, we needed to eliminate OVA-specific T cells and selectively stimulate Tcarbs. Therefore, we conducted in vitro experiments, stimulating splenic T cells from GBSIII-OVA-immunized mice with GBSIII-TT. By using this approach, we expanded T cell populations that recognized only GBSIII epitopes. We eliminated OVA-specific T cells in the splenic T cell pool because of the absence of OVA during in vitro expansion. In fact, after re-stimulation of immune lymphocytes with GBSIII-TT in vitro, we found that the frequency of carbohydrate-specific T cells was approximately one-third to one-half that of OVA-specific T cells.
In addition to the glycoconjugates used, the key steps involved in Tcarb isolation distinguish this protocol from others. To isolate Tcarbs, we had to optimize our protocol for many different variables through a number of steps, including the selection of in vitro stimulation procedures, the APC population and stimulation agents and incubation times that would maintain the highly sensitive Tcarbs. Below we list the crucial steps that we used to isolate Tcarbs, which would not have been isolated by traditional methods. An alternative method for Tcarb isolation is to immortalize T cells obtained from glycoconjugate-immunized mice by fusing them with a tumor cell line to obtain T cell hybridomas 13 . This approach has a major drawback, however: upon fusion of T cells with tumor cells, the T cells lose most of their in vivo and in vitro functional characteristics, and their utility for further characterization is thus limited.
This protocol is designed and optimized to isolate CD4 + T cells whose TCRs recognize only carbohydrate epitopes and not glycopeptides or peptides. This protocol is the first description of a method for the isolation of Tcarb clones. Several methodological steps differ from those used to isolate peptide-specific CD4 + T cell clones, as described in detail here.
Limitations
The limitations of our protocol for the preparation of glycoconjugate vaccines containing different polysaccharides may include the absence of a readily oxidizable terminal sialic acid in the carbohydrate to be conjugated. In such cases, carbohydrate moieties with 1,2-cis-diol functional groups can be sought for oxidation with periodate. Reaction conditions must be optimized for different carbohydrates. Alternative conjugation methods can also be sought 6, 16 . Limitations encountered in the isolation of Tcarbs may include different levels of viability of Tcarbs obtained from different polysaccharide antigens conjugated with carrier proteins. In our experience, Tcarbs are highly sensitive to incubation conditions and stimulation factors. Therefore, optimizing parts of the protocol (e.g., the duration of in vitro T cell stimulation, the concentration of antigens used for stimulation, the number and type of APCs used for stimulation) must be considered.
Applications of the method
We hope that this protocol will facilitate investigations into the interactions of glycoconjugate vaccines with Tcarbs, ultimately contributing to the development of novel, more immunogenic carbohydrate-based vaccines that are effective against many bacterial pathogens. Potential applications of this protocol include investigation of the roles of other bacterial carbohydrate antigens (e.g., those found in pathogens such as Staphylococcus aureus, S. pneumoniae and N. meningitidis) in the stimulation of the T cell-mediated adaptive immune response 10 . In addition, other pathogenic microorganisms, including viruses, parasites and fungi, also contain carbohydrate virulence factors 17 . The discovery of novel approaches for enabling these carbohydrates to induce T cell activation may prove greatly beneficial in combating these disease-causing organisms.
Experimental design
The isolation of Tcarbs requires two glycoconjugate vaccines containing the same polysaccharide (e.g., GBSIII) and a different carrier protein (e.g., OVA or TT). In this protocol, we isolated Tcarb clones that are stimulated by carbohydrate epitopes generated from either GBSIII-OVA or GBSIII-TT. However, this protocol can be adapted to study Tcarbs stimulated by other carbohydrates. Depending on the structure of the polysaccharide of interest, conjugation reactions may differ. If reductive amination is suitable for the polysaccharide used (e.g., polysaccharide containing a sialic acid or a monosaccharide with vicinal diol group within its structure), then this protocol can readily be applied to the conjugation of the polysaccharide with a carrier protein. Isolation of the Tcarbs can also be adapted for use with other glycoconjugate vaccines. First, GBSIII oxidation with sodium periodate is followed by conjugation with OVA or TT via a reductive amination reaction to obtain GBSIII-OVA or GBSIII-TT. The conjugation reaction section (PROCEDURE Steps 10-16) describes the conjugation of GBSIII with OVA. In the protocol for the generation and isolation of Tcarbs, GBSIII-TT is also used as an antigen. The conjugation of GBSIII to TT is carried out in the same way as the conjugation of GBSIII to OVA.
Next, groups of BALB/c mice are immunized with GBSIII-OVA to enrich for carbohydrate-specific T cells in the lymphoid organs. Isolated lymphocytes from draining lymph nodes are then cultured in vitro in the presence of III-TT. After this incubation, CD4 + T cells are purified and incubated again, this time in medium containing 10% T cell culture supplement. Meanwhile, splenocytes from GBSIII-OVA-immunized mice are isolated, irradiated and then cultured with in vitro-expanded CD4 + T cells (as described above) in the presence of GBSIII-TT. This treatment results in the isolation of a Tcarb line. Finally, these highly enriched CD4 + T cells are cloned by limiting dilution. The specificity and function of T cells obtained after in vitro incubations and limiting dilutions can be evaluated by interleukin (IL)-2 and IL-4 ELISpot assays. Stimulations with GBSIII, OVA, TT or no antigen serve as controls in the ELISpot assays. Tcarbs can be assessed when T cells are stimulated by both GBSIII-OVA and GBSIII-TT and not stimulated by GBSIII, OVA, TT or no antigen. Stimulation of a T cell population by one of the two glycoconjugates (GBSIII-OVA or GBSIII-TT) but not by the other is interpreted as evidence of carrier-protein specificity in that T cell population. This interpretation can be validated by stimulation of the same T cell population by the carrier protein alone. We prepare fresh solution every 2 months. GBSIII-OVA solution Reconstitute GBSIII-OVA with PBS at a concentration of 1 mg ml − 1 and sterilize by passage through a filter (pore size, 0.22 µm). This solution can be stored at 4 °C for up to ~4 weeks under sterile conditions. Any sign of cloudiness or precipitation in the solution may indicate aggregation, degradation or contamination of the glycoconjugate; therefore, when these signs are observed, prepare a fresh solution.
•
GBSIII-TT solution Reconstitute GBSIII-TT with PBS at a concentration of 1 mg ml − 1 and sterilize by passage through a filter (pore size, 0.22 µm). This solution can be stored at 4 °C for up to ~4 weeks under sterile conditions. Any sign of cloudiness or precipitation in the solution may indicate aggregation, degradation or contamination of the glycoconjugate; therefore, when these signs are observed, prepare a fresh solution. GBSIII-OVA/CFA emulsion Mix a 400-µl volume of GBSIII-OVA at 1 mg ml − 1 with 600 µl of PBS; then, emulsify with 1 ml of CFA by interchangeable syringes and emulsifying needles. Use freshly made emulsion for immunizations.  crItIcal To ensure that the emulsion is well formed, centrifuge the solution in a 1.5-ml Eppendorf tube at 800g for 1 min and confirm the lack of oil separation. GBSIII-OVA/IFA emulsion Mix a 400-µl volume of GBSIII-OVA at a concentration of 1 mg ml − 1 with 600 µl of PBS; next, emulsify with 1 ml of IFA by interchangeable syringes and emulsifying needles. proceDure GBsIII oxidation • tIMInG 1 d 1| Dissolve GBSIII (10 mg) to a concentration of 20 mg ml − 1 in 0.1 M acetate buffer (pH 5) in a 1-dram vial.  crItIcal step For this protocol, procedures are written for 10 mg of GBSIII as a starting material. However, various amounts of GBSIII (from ~1 mg to ~30 mg or more) can be used. The largest amount of GBSIII that we conjugated with OVA was 30 mg. The conjugation reaction can be scaled up.
2|
Prepare 0.01 M sodium periodate solution in 0.1 M acetate buffer.
3|
Calculate the amount of sodium periodate needed for oxidation of the side chain sialic acid residues located in each repeating unit of GBSIII ( Fig. 1) . Treatment of GBSIII with sodium periodate yields a reactive aldehyde at position C-8 of the terminal sialic acid of the repeating unit of GBSIII (ref. 18 ).  crItIcal step To achieve approximately equal weight contents of GBSIII and OVA in the final GBSIII-OVA product, the amount of sodium periodate is optimal at 0.5 molar equivalents of GBSIII. Therefore, per mole of each repeating unit of GBSIII, 0.5 mol of sodium periodate is needed for an oxidation reaction; that is, 10 mg of GBSIII (9.8 µmol of repeating units) is reacted with 490 µl of 0.01 M sodium periodate (4.9 µmol).
4|
While stirring the GBSIII solution on a stir plate at room temperature (RT, 25 °C), add sodium periodate (490 µl).
5|
Incubate the reaction mixture in the dark for 90 min at RT.  crItIcal step Aldehydes are light sensitive. To prevent any decomposition of the aldehydes formed, the reaction should be performed in the dark.
6|
Quench any unreacted sodium periodate by the addition of 100 µl of ethylene glycol.
7|
Desalt and purify the oxidized GBSIII on a Sephadex G-25 M desalting column (PD-10 column) in deionized water according to the manufacturer's protocol. Collect the oxidized GBSIII fraction (3.5 ml) and pass it through a sterile filter (pore size, 0.22 µm).
8|
Freeze the oxidized GBSIII fraction on dry ice and lyophilize it overnight by freeze drying.
9|
Weigh the oxidized GBSIII to determine the amount recovered. The yield in this reaction is ~80% (~8 mg of oxidized GBSIII).  crItIcal step Although oxidized GBSIII can be stored in the dark at − 20 °C as a powder, as aldehydes are highly sensitive functional groups and they are crucial for the conjugation reaction in the next step, we recommend continuing with the conjugation immediately after purification of oxidized GBSIII. 11| Weigh OVA to obtain a 1.5 weight equivalent of GBSIII (i.e., 12 mg). Dissolve OVA to a concentration of 20 mg ml − 1 in 0.1 M sodium bicarbonate (pH 8.3) in a 1-dram vial.  crItIcal step The amount of OVA is optimized at a 1.5 weight equivalent of GBSIII to achieve a 40-60% OVA weight content in the final GBSIII-OVA product.
12|
Transfer the OVA solution to the GBSIII solution while stirring the GBSIII solution on a stir plate at RT under a ventilation hood.
13|
Quickly add a molar-excessive amount of sodium cyanoborohydride (~10 mg) to the oxidized-GBSIII-OVA reaction mixture while stirring.  crItIcal step Sodium cyanoborohydride is a hygroscopic chemical whose exposure to air before a conjugation reaction dampens its conjugation reactivity (reductive amination reactivity). We buy this chemical in 100-mg capsules prepared under nitrogen. We break each capsule and divide its contents into ~10-mg portions in 1-dram vials filled with nitrogen gas under the ventilation hood. Furthermore, we store these vials in a desiccator at RT. ? trouBlesHootInG
14|
Incubate the vials at RT for 1 h. Next, transfer the reaction mixture to a 37 °C room (or place the vial in a 37 °C water bath on a stir plate) and continue stirring. Reaction yields are optimized at 37 °C and are higher than those at RT.  crItIcal step Gelling or precipitation of the reaction mixture takes place if multiple polysaccharide and protein molecules spontaneously interact to form matrix-like, cross-linked conjugates that are too large to remain in solution.
Conjugation reactions involving GBSIII almost never yield precipitates, because GBSIII is relatively small (~100 kDa) in comparison with some other bacterial polysaccharides (e.g., >100 kDa) that are more susceptible to precipitation. Nevertheless, two actions will prohibit any precipitation of the conjugation product. First, keep the reaction vial at RT for the first hour before transferring it to 37 °C. Second, closely monitor the reaction vial for the first hour for signs of gelling or precipitation; if such signs are seen, remove the reaction vial immediately from the 37 °C environment to RT, add 1 ml of water while stirring, and then keep the mixture at RT for the remainder of the reaction. ? trouBlesHootInG 15| Monitor the completion of the conjugation reaction at various intervals (e.g., 0, 24, 48 and 72 h). Remove 25-µl aliquots at the specified time points, add sodium bicarbonate (0.1 M) to a final volume of 500 µl and run the solution on a Superdex 200 gel permeation chromatography (GPC) column. Completion of the reaction is documented by monitoring the elution profile of OVA in the reaction mixture on the GPC column; unlike GBSIII, OVA absorbs ultraviolet light at 280 nm. OVA in its intact form elutes from the GPC column at 78-94 ml of the elution volume. GBSIII-bound OVA elutes at an earlier elution volume (46-62 ml); this result indicates a major shift in the molecular size of the OVA-containing conjugate (Fig. 2a) . The conjugation reaction is complete when there is no more change in the intensity of the GBSIII-OVA peak at the GPC elution profile of the conjugation product (Fig. 2a) . Conjugation of GBSIII and OVA reached completion in 48 h under the conditions specified here (Fig. 2a) . GPC separation of the reaction product (GBSIII-OVA) is described in detail in Steps 17-26.
16|
Terminate the conjugation reaction by adding an excessive amount of sodium borohydride (~10 mg) to the reaction vial. Aldehyde groups on the sialic acids that have not reacted with OVA are reduced to alcohol groups by sodium borohydride. Incubate the reaction mixture at RT for 1 h. 
18|
Load the filtered solution onto a Superdex 200 GPC column that is connected to a BioLogic HR FPLC system.
19|
Run the sample through the column at a flow rate of 1.0 ml min − 1 , with PBS as the eluent.
20|
Assay 2-ml fractions for their absorbances at 280 nm to determine the elution profile based on OVA (Fig. 2a) .
21|
Collect fractions corresponding to an elution volume of 50-62 ml (fractions 25-31) and dialyze them against deionized water (2 liters) in a dialysis membrane (MWCO 12,000-14,000 Da) for 48 h at 4 °C, changing the water three times.
22|
Lyophilize the purified GBSIII-OVA (2-3 d) by freeze drying.
23|
Weigh the purified GBSIII-OVA to determine the amount recovered. Approximately 10 mg of GBSIII-OVA should be recovered after this reaction.
24|
Prepare a 1 mg ml − 1 solution of GBSIII-OVA in PBS for characterization.
25|
Measure the protein content of GBSIII-OVA by using the microplate procedure with the BCA protein assay kit. Use 25-µl replicates of GBSIII-OVA (unknown: 1 mg ml − 1 ) or GBSIII (negative control: 1 mg ml − 1 ), or use varying concentrations of OVA (we used concentrations of 1, 0.5, 0.25, 0.125 and 0.06 mg ml − 1 ) to generate a standard curve for the identification of the OVA content in GBSIII-OVA. OVA weight content should be 45% for the conjugation product (GBSIII-OVA) described here.  crItIcal step In ruling out the possibility that Tcarbs are driven by unconjugated OVA, it is important to confirm the absence of unconjugated OVA in purified GBSIII-OVA. To this end, perform SDS-PAGE. Load the precast SDS-PAGE gel (Criterion TGX gel) with purified GBSIII-OVA (1 mg ml − 1 , 10 µl), GBSIII (1 mg ml − 1 , 10 µl), OVA (1 mg ml − 1 , 10 µl) or a protein ladder standard and run the gel according to the manufacturer's guidelines. We visualize the protein-containing bands on the gel with the ChemiDoc MP imager. This visualization technique requires the specified precast gels used here and is a stain-free alternative to Coomassie blue staining of protein bands on a gel. As shown in Figure 2b , purified GBSIII-OVA should not show an OVA band at 45 kDa. GBSIII should be loaded as a control to demonstrate that visualization is protein specific. The smeared band detected for GBSIII-OVA is typical for carbohydrate-containing molecules, as, unlike proteins, polysaccharides are heterogeneous in size and do not elute uniformly in gels. If the GBSIII-OVA contains unconjugated OVA, reseparate it on a Superdex 200 GPC column. Figure 2c . We collected fractions corresponding to an elution volume of 46-62 ml (fractions 23-31, Fig. 2c ) for purification of GBSIII-TT and processed them as described above for GBSIII-OVA purification.
Mouse immunization • tIMInG 4 weeks 27|
Immunize three BALB/c mice with 50 µl of GBSIII-OVA/CFA emulsion (containing 10 µg of GBSIII-OVA) by subcutaneous injection at the base of the tail. Return the mice to their normal housing conditions.
28|
Four weeks later, intraperitoneally boost the primed mice with 50 µl of GBSIII-OVA/IFA emulsion (containing 10 µg of GBSIII-OVA) and then return the mice to their normal housing conditions. preparation of mouse lymphocytes • tIMInG 2 h 29| Euthanize primed and boosted mice by CO 2 inhalation 10-14 d after boosting.
30|
Lay each mouse on its back on the dissecting board, fixing the forelegs upward and the hind legs downward with pins.
31| Surface-sterilize the skin with 70% (vol/vol) ethanol/H 2 O or a proprietary compound.
32|
Cut the skin along the left caudal side of the rib cage and the abdominal midline; next, expose the spleen with sterile surgical instruments (forceps and scissors).
33|
Remove the spleen with sterile surgical instruments and trim away the fatty tissue.  crItIcal step Do not discard the rest of the mouse, as this is needed for the isolation of lymphocytes in Step 38.
34|
Squeeze the spleen between the rough surfaces of two sterilized glass slides to prepare a single splenocyte suspension in a 60-× 15-mm polystyrene Petri dish containing 5 ml of cold washing medium. Transfer the splenocyte suspension into a 50-ml conical tube by passage through a cell strainer (pore size, 40 µm).
35|
Wash splenocytes by adding 20 ml of washing medium for cells obtained from one spleen, centrifuging at 250g for 5 min at 4 °C and discarding the supernatant.
36|
To separate erythrocytes from splenocytes, resuspend the cell pellet in 5 ml of ACK lysing buffer for 5 min at RT, and then dilute the mixture with 45 ml of washing medium. Centrifuge at 250g for 5 min and remove the supernatant.
37| Wash the cells twice more as described in
Step 35 and then count the number of splenocytes by resuspending them in 20 ml of culture medium and diluting 10 µl of the cell suspension 1,000-fold in 10% (vol/vol) trypan blue. Follow this by filling a chamber of a hemocytometer with the diluted cell suspension and counting the number of cells under the microscope. Keep splenocytes stored on ice while isolating the lymphocytes.
38|
Take the rest of the mouse from which the spleen was isolated in Step 33 and cut the skin along the abdominal midline and quadriceps muscles; next, expose the popliteal lymph nodes with sterile surgical instruments (forceps and scissors).
39| Dissect out and place the lymph nodes into a 60-× 15-mm polystyrene Petri dish containing 5 ml of cold washing medium.
40|
In one hand, hold each lymph node with a 21-G needle locked onto a 3-ml syringe; with the other hand, gently strip out the capsule membrane of the lymph node, using a 25-G needle locked onto a 3-ml syringe. By this method, lymphocytes can be teased out from the lymph nodes and released into the medium.  crItIcal step It is important to gently tease lymphocytes out from the lymph node capsule in order to avoid collecting cells other than lymphocytes.
41|
Collect the cell suspension, pass it through a cell strainer (pore size, 40 µm) and transfer the filtered cell suspension into a 50-ml conical tube.
42|
Wash lymphocytes with washing medium by resuspending them in 10 µl of washing medium, centrifuging at 250g for 5 min and discarding the supernatant. Repeat the wash twice.
43|
Pass splenocytes and lymphocytes through separate 40-µm cell strainers in order to remove cell clumps.  crItIcal step Cell clumps will ultimately hamper lymphocytes from growing in culture.
44|
Count the number of lymphocytes in the hemocytometer by microscopy as described in Step 37. Set aside the majority of the lymphocytes to generate GBSIII-specific T cell lines by in vitro expansion of CD4 + T cells as in Steps 46-71. Set aside several million lymphocytes, keeping them on ice, for an evaluation of specificity for the carbohydrate portion of the glycoconjugate antigens. This is determined by IL-2 and IL-4 ELISpot assays, which are performed on the same day ( Fig. 3a; described in Step 72A).  crItIcal step It is important to ascertain the presence of Tcarbs in primary immune lymphocytes before proceeding to the next step.
Generation of tcarb lines • tIMInG 4-6 weeks 45|
Set aside the number of splenocytes (obtained in Step 37 above) necessary to coculture with lymphocytes and irradiate them at 3,000 rad for use as APCs. Freeze down the remaining splenocytes at a density of 5 × 10 6 per ml in a cryovial in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) DMSO and store them in a liquid nitrogen tank.
46|
Resuspend lymphocytes and splenocytes at a concentration of 3 × 10 6 per ml each in CRPMI supplemented with 0.5% (vol/vol) hiNMS.  crItIcal step It is important to use hiNMS instead of hiFCS in order to prevent the growth of nonspecific T cells in culture.
47| Mix 1 ml of lymphocytes with 2 ml of irradiated splenocytes (both at 3 × 10 6 per ml) in CRPMI supplemented with 0.5% (vol/vol) hiNMS in the presence of GBSIII-TT antigen (100 µg ml − 1 ) and place the entire mixture into one well of a 12-well plate; culture the mixture at 37 °C in a 5% CO 2 incubator.
48|
After incubation for 3 d, replace one-half of the volume of the culture medium with freshly made CRPMI supplemented with 10% (vol/vol) hiFCS and continue culturing the cells at 37 °C in a 5% CO 2 incubator.
49|
Two days later, collect the cells and wash them once with washing medium by centrifugation at 250g for 5 min.
50|
Resuspend the cells in 25 ml of washing medium, and then lay down the suspension on top of 15 ml of Lympholyte-M in a 50-ml conical tube.
51|
Centrifuge this preparation at 500g for 20 min at RT.  crItIcal step This step should be performed at RT to yield a density gradient for the separation of live lymphocytes in good condition. 52| Collect cells from the interface between the washing medium and Lympholyte-M. Resuspend the cells in 40 ml of washing medium, and then centrifuge this preparation at 250g for 5 min at 4 °C.  crItIcal step Purification of lymphocytes with Lympholyte-M should make the lymphocytes more viable by removing toxic substances and dead cells.
53|
Wash the cells twice with washing medium by centrifugation at 250g for 5 min.
54|
Count the lymphocytes and confirm that the majority are alive by trypan blue staining; resuspend the lymphocytes at a density of 3 × 10 6 per ml in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS, place 1 ml of the suspension in one well of a 24-well plate and incubate the plate at 37 °C in a 5% CO 2 incubator for 3 d.  crItIcal step TCCS should be added to the culture 5-6 d after stimulation with the antigen (when the lymphocytes are well rested).
55|
Three days later, replace one-half of the volume of the culture medium with freshly made CRPMI supplemented with 0% (vol/vol) hiFCS and 10% (vol/vol) TCCS. If the cells are overcrowded (more than a monolayer), split them into two or three wells.
56|
Incubate the cells for another 2-3 d.
57|
By removing a cryovial from a liquid nitrogen tank and holding it in a 37 °C water bath until the sides are thawed but the center remains frozen, thaw the frozen splenocytes from GBSIII-OVA-immunized BALB/c mice stored in Step 45. Next, irradiate thawed splenocytes at 3,000 rad and use them as APCs, as described in Step 45.
58| Count the live lymphocytes (from
Step 56 or 62) and APCs (from Step 57). Resuspend the lymphocytes at a density of 2 × 10 6 per ml and the APCs at a density of 8 × 10 6 per ml in CRPMI supplemented with 10% (vol/vol) hiFCS without TCCS.
59|
Mix 0.5 ml of lymphocytes at a density of 2 × 10 6 per ml and 0.5 ml of APCs at a density of 8 × 10 6 per ml in the presence of the GBSIII-TT antigen (100 µg ml − 1 ). Place the entire mixture in a single well of a 24-well plate and incubate the plate at 37 °C in a 5% CO 2 incubator.
60|
After 3 d, replace one-half of the volume of the culture medium with freshly made CRPMI supplemented with 10% (vol/vol) hiFCS.
61|
Incubate the plate for another 2-3 d. Thereafter, collect the cells, purify them with Lympholyte-M as in Steps 50-53 and culture them as described in Steps 54-56.
62|
Collect the cultured cells, set aside one-half of the cells and stimulate the other half of the cells for one more round as in Steps 57-60. At this stage, the growing cells should be enriched for Tcarbs, the result being a 'Tcarb line.' Put aside several hundred thousand Tcarb-line cells for testing of specificity for the carbohydrate portion of the glycoconjugate antigens as determined by an IL-2 ELISpot assay ( Fig. 3b; Step 72A). Freeze these cells in a vial and store them in a liquid nitrogen tank.
Generation of tcarb clones • tIMInG 2-3 months 63| Take the remaining cells from
Step 62 and dilute them in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS at serial concentrations of 10 per ml, 100 per ml and 1,000 per ml. Next, place the diluted cells into the wells of a 96-well plate at concentrations of 1 cell per 100 µl, 10 cells per 100 µl and 100 cells per 100 µl.
64|
Thaw frozen splenocytes from GBSIII-OVA-immunized BALB/c mice, irradiate the cells and use them as APCs (as described in Step 57); resuspend these cells at a density of 7 × 10 5 per 100 µl in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS in the presence of GBSIII-TT antigen (200 µg ml − 1 ). Place the APCs (at a concentration of 7 × 10 5 per 100 µl) into each well of the 96-well plate that contains the serial dilutions of T cells, as set up in Step 63.
65|
Coculture the cloned T cells and APCs for 14 d at 37 °C in a 5% CO 2 incubator, replacing one-half of the volume of the culture medium with freshly made CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS every 2-3 d.
66|
Every 2 weeks, re-stimulate the cloned T cells by adding 7 × 10 5 cells per 100 µl of APCs in the presence of the GBSIII-TT antigen (100 µg ml − 1 ) to each well until the growth of the cloned T cells becomes visible under the stereomicroscope. When the cloned T cells fully occupy the well (monolayer) of the 96-well plate, transfer the cells into a larger well (24-well plate) with a greater number of APCs (3 × 10 6 cells per 1 ml per well) in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS.
67|
Count the cells and set aside a few hundred thousand cloned T cells for the determination of the surface phenotype (CD4 or CD8) by flow cytometric analysis ( Fig. 4a; Step 72B). These cloned T cells should also be used in determining the specificity for the carbohydrate portion of the glycoconjugate antigens by IL-2 ELISpot assay ( Fig. 4b; Step 72A).
Continue to incubate the remainder of the cells as described in
Step 68.
Maintenance of tcarb clones
• tIMInG up to 2-3 months 68| Incubate 2 × 10 6 cells from a Tcarb clone and 2 × 10 7 APCs in one well of a six-well plate in the presence of the GBSIII-TT antigen (100 µg ml − 1 ) in CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS at 37 °C in a 5% CO 2 incubator for 3 d.
69|
After the 3-d incubation period, replace one-half of the volume of the medium with freshly made CRPMI supplemented with 10% (vol/vol) hiFCS and 10% (vol/vol) TCCS.
70|
One week later, purify T cells with Lympholyte-M as described in Steps 50-53, and then place 2 × 10 6 cloned Tcarbs in one well of a six-well plate.
71|
Incubate the cells for another week; next, re-stimulate cloned Tcarbs with APCs and GBSIII-TT antigen as described in
Step 68. ? trouBlesHootInG Troubleshooting advice can be found in table 1.
Detection of primary tcarbs and of tcarb lines and clones
• Figure 3a , there are certainly a number of lymphocytes-presumably T cells-that should secrete both IL-2 and IL-4 in response to OVA and GBSIII-OVA antigen. However, it is noteworthy that significantly more lymphocytes are able to respond to GBSIII-OVA than to OVA. Moreover, a considerable number of lymphocytes can respond to GBSIII-TT even though they are obtained from GBSIII-OVA-immunized mice. Finally, neither GBSIII nor TT alone should stimulate the lymphocytes. Thus, certain populations of lymphocytes derived from GBSIII-OVA-immunized mice can react with the GBSIII portion of GBSIII-OVA or GBSIII-TT, but not with GBSIII alone.
Detection of tcarb lines by elIspot assay
After three rounds of in vitro GBSIII-TT antigen stimulation and resting of the T cells for >10 d after the last stimulation, Tcarb lines should be collected and their antigenic specificities be determined by an IL-2 ELISpot assay. As shown in Figure 3b , the relative proportion of T cells that react with either GBSIII-OVA or GBSIII-TT should increase drasticallyi.e., by >2,000-fold over the results of the immediate ex vivo ELISpot assays shown in Figure 3a . Because the number of T cells that react with OVA alone has almost completely diminished, most of the GBSIII-OVA-or GBSIII-TT-reactive T cells shown in Figure 3b should recognize the GBSIII portion of the respective glycoconjugate antigens. At this stage, these T cells approach equivalence to a T cell line in that >50% recognize the GBSIII portion of the glycoconjugates. Therefore, these T cells can be used to generate Tcarb clones by limiting dilution, as described in the Procedure section.
Detection of tcarb clones by flow cytometric analysis and elIspot assay
After successfully isolating cloned Tcarbs by limiting dilution and expanding them to sufficient numbers, subject cloned Tcarbs to flow cytometric analysis and ELISpot assays to determine their CD4/CD8 phenotype and antigen specificity, respectively. Figure 4a shows the staining profile of one representative Tcarb clone, 2B11, which expresses αβTCR chains together with CD3 to form a CD3-αβTCR complex. This also shows that clone 2B11 expresses CD4 + but not CD8 + molecules (Fig. 4a) . Thus far, we have generated more than four Tcarb clones from GBSIII-immunized BALB/c mice, and all these clones are CD4 + CD8 -cells (data not shown). The antigen specificities of clone 2B11 against the GBSIII portion of the glycoconjugates have been confirmed by an IL-2 ELISpot assay (Fig. 4b) . In addition, when anti-CD4 or anti-CD8 antibody is added to the ELISpot assay, only anti-CD4 antibody-and not anti-CD8 antibody-completely inhibits the response of cloned Tcarbs to GBSIII-OVA or GBSIII-TT. This result not only correlates with the surface phenotype of the Tcarb clone determined by flow cytometric analysis but also indicates that CD4 molecules expressed on the Tcarb clone contribute to the recognition of the GBSIII portion of the glycoconjugate antigens.
Antigen-specific T cell responses can also be evaluated by the traditional tritiated thymidine ([ 3 H]-TdR) incorporation method, which requires a radioactive scintillation counter. Fluorescence-based assays (nonradioactive) for cell proliferation are likewise readily available. The cell proliferation assay kit from Invitrogen (cat. no. C7026) or Biomedica Medizinprodukte (cat. no. BI5000) can be substituted for the [ 3 H]-TdR assay.
Finally, we wish to emphasize that all the methods described in this study for GBIII-OVA and GBSIII-TT, particularly the ELISpot assay and flow cytometric analysis, can be readily adapted for primary Tcarbs, Tcarb lines and clones that recognize other carbohydrates. 
